Infinity (INFI) Reports Narrower-than-Expected Loss In Q1
Zacks Investment Research | May 09, 2017 09:58PM ET
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) reported a loss of 21 cents per share in first-quarter 2017, narrower than the Zacks Consensus Estimate loss of 22 cents. Also, the company had reported loss of 82 cents in the year-ago quarter.
Since Infinity does not have any approved product in its portfolio, the company earns revenues in the form of royalties, license and milestone payments as well as research and development (R&D) support fees paid by its partners.
Infinity did not record any revenue during first-quarter 2017. But it had recorded collaboration revenue of $9.3 million in the year-ago quarter, related to Infinity's previous collaboration agreement with AbbVie Inc. (NYSE:ABBV) .
Infinity’s share price has increased 36.3% year to date, while the Zacks classified Medical-Drugs industry gained 3.3%.
Quarter in Detail
In the reported quarter, Research and Development (R&D) expenses plummeted 89.7% to $4.03 million. The decline was mainly related to a decrease in clinical development expenses for duvelisib in addition to the company's 2016 restructuring activities.
General and administrative (G&A) expenses were $6.44 million for the reported quarter, down 40.6% year over year. The decrease was mainly due to the company's 2016 restructuring activities.
Currently, Infinity is evaluating IPI-549 as a monotherapy and in combination with Opdivo (nivolumab) in a phase I study in patients with advanced solid tumors.
The company anticipates completing the monotherapy dose-escalation phase of the study in the first half of 2017. Also, it expects to initiate patient enrolment in the monotherapy expansion cohort in the second half of 2017. In addition, it plans to complete the dose-escalation phase evaluating IPI-549 in combination with Opdivo in the same period, and initiate multiple combination expansion cohorts as well.
2017 Outlook
In 2017, Infinity expects net loss to be in the range of $40 million to $50 million. The Zacks Consensus Estimate is pegged at a loss of $1.03 per share. Moreover, the company anticipates ending 2017 with year-end cash and cash equivalents and available-for-sale securities balance in $40 million to $50 million band.
Get The News You Want
Zacks Rank & Stocks to Consider
Infinity currently holds a Zacks Rank #2 (Buy). Other favorable ranked stocks in the health care sector include Galena Biopharma, Inc. (NASDAQ:GALE) and BioTime, Inc. (NYSE:BTX) . While Galena sports a Zacks Rank #1 (Strong Buy), BioTime carries a Zacks Rank #2 (Buy) .You can see .
Galena’s loss per share estimates narrowed from $2.03 to 58 cents for 2017 over the last 60 days. The company posted positive earnings surprises in two of the four trailing quarters, with an average beat of 53.83%.
BioTime’s loss per share estimates narrowed 60.9% to 18 cents for 2017 over the last 60 days. The company posted a positive earnings surprise in two of the four trailing quarters with an average beat of 12.32%.
Looking for Ideas with Even Greater Upside?
Today's investment ideas are short-term, directly based on our proven 1 to 3 month indicator. In addition, I invite you to consider our long-term opportunities. These rare trades look to start fast with strong Zacks Ranks, but carry through with double and triple-digit profit potential. Starting now, you can look inside our home run, value, and stocks under $10 portfolios, plus more. Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.